Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
NCT06347185 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2025-07-17
Summary
This is a late phase II, prospective, multicenter randomized study, to assess the value of early palliative care integrated with the standard oncologic care in patients with Recurrent Metastatic (RM) Head and Neck Cancer (HNC) proposed to first line palliative systemic treatment.
The study randomizes patients in a 1:1 fashion to standard oncologic care, in which the palliative care is requested as needed (reactive approach) or to early palliative care integrated with the standard oncologic care (proactive approach).
Standard of Care: the oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise. The oncologist will base the choices also upon the results of the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
Integrated approach: Besides the Oncology visit, patient will have the palliative care expert visit and follow up. The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to a validated instrument (the PCI-H\&N) and patient priority questionnaire's results.
Stratification Factors
* Institution
* Performance Status (PS) (0 vs 1-2)
* Presence of any caregiver at home
* Type of treatment (Immunotherapy alone vs any other combination)
Study duration: the total study duration is estimated at 36 months, with a total accrual time estimated to be 24 months from first patient in (FPI) and with an additional follow-up period of 12 months.
End of study occurs when all patients have completed their end of study visit and the study is mature for all analyses defined in the protocol and the database has been cleaned and frozen for these analyses.
Conditions
- Head and Neck Neoplasms
Interventions
- PROCEDURE
-
Early palliative care, integrated with the standard oncologic care (proactive approach)
Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.
- PROCEDURE
-
Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
Sponsors & Collaborators
-
European Organisation for Research and Treatment of Cancer - EORTC
lead NETWORK
Principal Investigators
-
Paolo Bossi, MD · Istituto Clinico Humanitas
-
Kathy Taylor, MSc · Universitätsmedizin Mainz - Institut fuer Medizinische -Biometrie, Epidemiologie und informatik
-
Luigi Lorini, MD · Istituto Clinico Humanitas
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-30
- Primary Completion
- 2027-04-30
- Completion
- 2028-12-31
More Related Trials
-
Studying Survivorship Care Plans in Head and Neck Cancer
NCT03106090 ·Status: TERMINATED ·Phase: NA
-
Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
NCT00002476 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
NCT02474368 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00006248 ·Status: COMPLETED ·Phase: PHASE2
-
Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer
NCT02262221 ·Status: SUSPENDED ·Phase: NA
-
Chemo-embolization for Head and Neck Cancer
NCT04595981 ·Status: WITHDRAWN ·Phase: PHASE2
-
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
NCT00544414 ·Status: COMPLETED ·Phase: PHASE2
-
Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours
NCT03238378 ·Status: RECRUITING ·Phase: NA
-
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
NCT02296684 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01064479 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
NCT01142414 ·Status: WITHDRAWN ·Phase: PHASE3
-
Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal Cancer
NCT03367884 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
NCT00005647 ·Status: COMPLETED ·Phase: PHASE1
-
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
NCT00462735 ·Status: COMPLETED ·Phase: PHASE2
-
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
NCT02255097 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
NCT00872404 ·Status: TERMINATED ·Phase: PHASE2
-
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00095628 ·Status: COMPLETED ·Phase: PHASE2
-
Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer
NCT01254734 ·Status: TERMINATED ·Phase: NA
-
Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
NCT00904345 ·Status: TERMINATED ·Phase: PHASE2
-
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
NCT00033618 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC
NCT06793761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
NCT02252042 ·Status: COMPLETED ·Phase: PHASE3
-
Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC
NCT05459415 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
NCT07062354 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2